Testosterone cypionate

Product Details

Artificial synthesis of androgens
Cyclopentyltestosterone is an artificially synthesized androgen that is mainly used in clinical practice to treat epididymitis or epididymosis, functional uterine bleeding, excessive menstruation, endometriosis, uterine fibroids, menopausal syndrome, metastatic breast and ovarian cancer, elderly osteoporosis, aplastic anemia, etc.
pharmacological action 
Endogenous androgens are responsible for the normal growth and development of male sexual organs, maintaining secondary sexual characteristics, including the growth and maturation of the prostate, seminal vesicles, penis, and scrotum; Develop male hair distribution, such as beard, pubic bone, chest, and armpit hair; The enlargement of the throat, thickening of the vocal cords, and changes in the distribution of body muscles and fat. These drugs can also lead to the retention of phosphorus in nitrogen, sodium, potassium, and cadmium, and a decrease in urinary calcium excretion. It has been reported that androgens can increase protein synthesis metabolism and reduce protein catabolism. Androgens are responsible for the termination of linear growth during puberty and final growth spurts, caused by the fusion of the growth centers of the epiphyseal growth. In children, exogenous androgens accelerate linear growth rates, but may lead to disproportionate progress in bone maturation. Prolonged use may lead to the fusion of epiphyseal growth centers and the termination of the growth process. According to reports, androgens enhance the production of stimulating red blood cells and generate stimulating factors for red blood cell production. During the administration of exogenous androgens, endogenous testosterone release is inhibited by feedback inhibition of pituitary luteinizing hormone (LH).
Pharmacokinetics
The polarity of cyclopentropionic acid testosterone is smaller than that of free testosterone, and the testosterone ester in the injected oil is slowly absorbed from the lipid phase in the muscle; Therefore, testosterone cyclopropionate can be administered every two to four weeks. Testosterone in plasma binds to specific testosterone estradiol with 98% binding globulin, and about 2% is free. Generally speaking, the binding amount of this sex hormone, the globulin in the plasma, will determine the distribution and binding form of testosterone between free and testosterone, and the concentration of free testosterone will determine its half-life. Approximately 90% of the dose of testosterone is excreted in the urine as a combination of glucuronic acid and glucose; Approximately 6% of the dose is excreted in feces, mostly in an unbound form. The inactivation of testosterone is mainly in the liver, and testosterone is metabolized into various 17 ketosteroids through two pathways. During intramuscular injection, the half-life of testosterone cyclopropionate is approximately eight days.
Indications
1. Primary hypogonadism (congenital or acquired): Cryptorchidism caused by testicular failure, bilateral torsion, orchitis, testicular disappearance syndrome; Or orchiectomy.
2. Hypogonadotropism (congenital or acquired): Deficiency in gonadotropins or LHRH, or pituitary hypothalamic injury caused by tumors, trauma, or radiation.